http://www.stemcellthera.com/ () —
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) announced today that
it has restated its unaudited interim consolidated financial
statements for the quarter ended September 30, 2024 and will file the
restated Financial Statements on SEDAR on February 25, 2011. Upon
review it was determined that, as a result of a calculation error, the
non-cash expense for stock options was originally overstated by
$133,000 and accrued expenses for the period were understated by
$63,000, for a net decrease of Net Loss of $70,000.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a
public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development of
therapies that utilize drugs to stimulate a patient's own resident
stem cells. The Company's programs aim to repair brain and nerve
function lost due to disease or injury. The Company's extensive patent
portfolio of owned and licensed intellectual property supports the
potential expansion into future clinical programs in numerous
neurological diseases such as traumatic brain injury, multiple
sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com (http://www.stemcellthera.com) .
These securities have not been registered under the United States
Securities Act of 1933, as amended, or the securities laws of any
state, and may not be offered or sold within the United States or to,
or for the account or benefit of U.S. persons unless an applicable
exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause but are not limited
to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the
impact of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process and other
risks detailed from time to time in the Company's ongoing quarterly
and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.